Sharon Pok
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sharon Pok has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Arfianti Arfianti
Universitas Riau
3 shared publications - Geoffrey C. Farrell
Liver Research Group, ANU Medical School, Australian National University at The Canberra Hospital, Garran, ACT, Australia
3 shared publications - Narci C. Teoh
Gastroenterology and Hepatology Laboratory, Australian National University Medical School at The Canberra Hospital, Australian Capital Territory, Australia
3 shared publications Axel Ullrich
Department of Molecular Biology, Max-Planck-Institute of Biochemistry, Martinsried, Germany
2 shared publicationsGeorge N. Ioannou
Division of Gastroenterology and Hepatology, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle, WA
2 shared publicationsHooi Linn Loo
Singapore OncoGenome Laboratory, Institute of Medical Biology, A∗STAR, 8A Biomedical Grove, #06-06 Immunos, Singapore 138648, Singapore
2 shared publications
Latest Publications
- 1 July 2020
- Published by Elsevier in Journal of Hepatology
- Vol. 73 (1) , 140-148
Exercise retards hepatocarcinogenesis in obese mice independently of weight control
- 1 July 2020
- Published by Elsevier in Journal of Hepatology
- Vol. 73 (1) , 140-148
Exercise retards hepatocarcinogenesis in obese mice independently of weight control
- Open Access
- 26 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-13
Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling
The underlining mechanisms of dietary cholesterol and nonalcoholic steatohepatitis (NASH) in contributing to hepatocellular carcinoma (HCC) remain undefined. Here we demonstrated that high-fat-non-cholesterol-fed mice developed simple steatosis, whilst high-fat-high-cholesterol-fed mice developed NASH. Moreover, dietary cholesterol induced larger and more numerous NASH-HCCs than non-cholesterol-induced steatosis-HCCs in diethylnitrosamine-treated mice. NASH-HCCs displayed significantly more aberrant gene expression-enriched signaling pathways and more non-synonymous somatic mutations than steatosis-HCCs (335 ± 84/sample vs 43 ± 13/sample). Integrated genetic and expressional alterations in NASH-HCCs affected distinct genes pertinent to five pathways: calcium, insulin, cell adhesion, axon guidance and metabolism. Some of the novel aberrant gene expression, mutations and core oncogenic pathways identified in cholesterol-associated NASH-HCCs in mice were confirmed in human NASH-HCCs, which included metabolism-related genes (ALDH18A1, CAD, CHKA, POLD4, PSPH and SQLE) and recurrently mutated genes (RYR1, MTOR, SDK1, CACNA1H and RYR2). These findings add insights into the link of cholesterol to NASH and NASH-HCC and provide potential therapeutic targets.
- 26 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-13
Open AccessDietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling
The underlining mechanisms of dietary cholesterol and nonalcoholic steatohepatitis (NASH) in contributing to hepatocellular carcinoma (HCC) remain undefined. Here we demonstrated that high-fat-non-cholesterol-fed mice developed simple steatosis, whilst high-fat-high-cholesterol-fed mice developed NASH. Moreover, dietary cholesterol induced larger and more numerous NASH-HCCs than non-cholesterol-induced steatosis-HCCs in diethylnitrosamine-treated mice. NASH-HCCs displayed significantly more aberrant gene expression-enriched signaling pathways and more non-synonymous somatic mutations than steatosis-HCCs (335 ± 84/sample vs 43 ± 13/sample). Integrated genetic and expressional alterations in NASH-HCCs affected distinct genes pertinent to five pathways: calcium, insulin, cell adhesion, axon guidance and metabolism. Some of the novel aberrant gene expression, mutations and core oncogenic pathways identified in cholesterol-associated NASH-HCCs in mice were confirmed in human NASH-HCCs, which included metabolism-related genes (ALDH18A1, CAD, CHKA, POLD4, PSPH and SQLE) and recurrently mutated genes (RYR1, MTOR, SDK1, CACNA1H and RYR2). These findings add insights into the link of cholesterol to NASH and NASH-HCC and provide potential therapeutic targets.
- 1 April 2017
- Published by Elsevier in Experimental Cell Research
- Vol. 356 (1) , 48-56
Deriving and testing of dysplastic murine hepatocytes: A new platform in liver cancer research
- 1 April 2017
- Published by Elsevier in Experimental Cell Research
- Vol. 356 (1) , 48-56
Deriving and testing of dysplastic murine hepatocytes: A new platform in liver cancer research
- 30 May 2016
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 31 (6) , 1210-1219
Testosterone regulation of cyclin E kinase: A key factor in determining gender differences in hepatocarcinogenesis
Background and Aim: While gender differences in hepatocellular carcinoma (HCC) are profound, the mechanism is unclear. Using castration and hormone replacement strategies, we tested whether these gender differences are attributable to testosterone or estradiol/progesterone effects on cell cycle regulators and p53.Methods: We studied dysplastic liver and HCCs in intact and castrated diethylnitrosamine‐injected C57BL/6J male and female mice, with or without hormonal replacement. Effects of sex steroids on proliferation and survival of primary hepatocytes and primary HCC cells were also characterized.Results: Diethylnitrosamine‐injected female mice displayed fewer dysplastic foci and slower onset of HCC than male mice, with smaller/more differentiated tumors and fewer metastases. Castration of diethylnitrosamine‐injected male mice reduced cyclin E kinase and augmented hepatocyte apoptosis compared with intact male mice; estradiol/progesterone enhanced these effects. In intact female mice, cyclin E kinase activity was less than in males; testosterone administered to ovariectomized female mice upregulated cyclin E, increased cyclin E kinase, and accelerated hepatocarcinogenesis. In vitro, testosterone increased expression of cell cycle regulators (cyclin D1, cyclin E, and cyclin‐dependent kinase 2) and reduced p53 and p21, which enhanced hepatocyte viability. In contrast, estradiol both suppressed hepatocyte cell cycle markers, upregulated p53 and reduced viability of hepatocytes and HCC cells.Conclusions: Testosterone is the positive regulator of hepatocyte cell cycle via cyclin E, while estradiol plays a negative role by effects of p53 and p21. Together, both sex hormones determine the male predominance of gender differences in hepatocarcinogenesis.
- 30 May 2016
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 31 (6) , 1210-1219
Testosterone regulation of cyclin E kinase: A key factor in determining gender differences in hepatocarcinogenesis
Background and Aim: While gender differences in hepatocellular carcinoma (HCC) are profound, the mechanism is unclear. Using castration and hormone replacement strategies, we tested whether these gender differences are attributable to testosterone or estradiol/progesterone effects on cell cycle regulators and p53.Methods: We studied dysplastic liver and HCCs in intact and castrated diethylnitrosamine‐injected C57BL/6J male and female mice, with or without hormonal replacement. Effects of sex steroids on proliferation and survival of primary hepatocytes and primary HCC cells were also characterized.Results: Diethylnitrosamine‐injected female mice displayed fewer dysplastic foci and slower onset of HCC than male mice, with smaller/more differentiated tumors and fewer metastases. Castration of diethylnitrosamine‐injected male mice reduced cyclin E kinase and augmented hepatocyte apoptosis compared with intact male mice; estradiol/progesterone enhanced these effects. In intact female mice, cyclin E kinase activity was less than in males; testosterone administered to ovariectomized female mice upregulated cyclin E, increased cyclin E kinase, and accelerated hepatocarcinogenesis. In vitro, testosterone increased expression of cell cycle regulators (cyclin D1, cyclin E, and cyclin‐dependent kinase 2) and reduced p53 and p21, which enhanced hepatocyte viability. In contrast, estradiol both suppressed hepatocyte cell cycle markers, upregulated p53 and reduced viability of hepatocytes and HCC cells.Conclusions: Testosterone is the positive regulator of hepatocyte cell cycle via cyclin E, while estradiol plays a negative role by effects of p53 and p21. Together, both sex hormones determine the male predominance of gender differences in hepatocarcinogenesis.
- 28 February 2014
- Published by Wiley in Liver International
- Vol. 35 (1) , 240-253
miR‐181a mediates TGF‐β‐induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer
Background & Aims: Epithelial–mesenchymal transition (EMT) has been implicated in the processes of embryogenesis, tissue fibrosis and carcinogenesis. Transforming growth factor‐β (TGF‐β) has been identified as a key driver of EMT and plays a key role in the pathogenesis of cirrhosis and hepatocellular carcinoma (HCC). The aim was to identify microRNA (miR) expression in TGF‐β‐induced hepatocyte EMT.Methods: We treated a human hepatocyte cell line PH5CH8 with TGF‐β to induce an EMT‐like change in phenotype and then identified dysregulated miRs using TaqMan Low Density Arrays. MiR expression was altered using miR‐181a mimic and inhibitor in the same system and gene changes were identified using TaqMan gene arrays. MiR‐181a gene expression was measured in human and mouse cirrhotic or HCC liver tissue samples. Gene changes were identified in rAAV‐miR‐181a‐expressing mouse livers using TaqMan gene arrays.Results: We identified miR‐181a as a miR that was significantly up‐regulated in response to TGF‐β treatment. Over‐expression of a miR‐181a mimic induced an in vitro EMT‐like change with a phenotype similar to that seen with TGF‐β treatment alone and was reversed using a miR‐181a inhibitor. MiR‐181a was shown to be up‐regulated in experimental and human cirrhotic and HCC tissue. Mouse livers expressing rAAV‐miR‐181a showed genetic changes associated with TGF‐β signalling and EMT.Conclusions: MiR‐181a had a direct effect in inducing hepatocyte EMT and was able to replace TGF‐β‐induced effects in vitro. MiR‐181a was over‐expressed in cirrhosis and HCC and is likely to play a role in disease pathogenesis.
- 28 February 2014
- Published by Wiley in Liver International
- Vol. 35 (1) , 240-253
miR‐181a mediates TGF‐β‐induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer
Background & Aims: Epithelial–mesenchymal transition (EMT) has been implicated in the processes of embryogenesis, tissue fibrosis and carcinogenesis. Transforming growth factor‐β (TGF‐β) has been identified as a key driver of EMT and plays a key role in the pathogenesis of cirrhosis and hepatocellular carcinoma (HCC). The aim was to identify microRNA (miR) expression in TGF‐β‐induced hepatocyte EMT.Methods: We treated a human hepatocyte cell line PH5CH8 with TGF‐β to induce an EMT‐like change in phenotype and then identified dysregulated miRs using TaqMan Low Density Arrays. MiR expression was altered using miR‐181a mimic and inhibitor in the same system and gene changes were identified using TaqMan gene arrays. MiR‐181a gene expression was measured in human and mouse cirrhotic or HCC liver tissue samples. Gene changes were identified in rAAV‐miR‐181a‐expressing mouse livers using TaqMan gene arrays.Results: We identified miR‐181a as a miR that was significantly up‐regulated in response to TGF‐β treatment. Over‐expression of a miR‐181a mimic induced an in vitro EMT‐like change with a phenotype similar to that seen with TGF‐β treatment alone and was reversed using a miR‐181a inhibitor. MiR‐181a was shown to be up‐regulated in experimental and human cirrhotic and HCC tissue. Mouse livers expressing rAAV‐miR‐181a showed genetic changes associated with TGF‐β signalling and EMT.Conclusions: MiR‐181a had a direct effect in inducing hepatocyte EMT and was able to replace TGF‐β‐induced effects in vitro. MiR‐181a was over‐expressed in cirrhosis and HCC and is likely to play a role in disease pathogenesis.
- 22 August 2013
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 28 (9) , 1545-1554
Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis
Background and Aim: By array‐comparative genomic hybridization, we demonstrated cyclin E as one of seven genes associated with hepatocellular carcinoma (HCC) development in Ku70 DNA repair‐deficient mice. We therefore explored the hypothesis that during hepatocarcinogenesis, cyclin E kinase can overcome the inhibitory effects of p53 and establish whether abnormal miRNA(mi‐R)‐34, a co‐regulator of cyclin E and p53, can account for their interactions as “drivers” of HCC.Methods: Dysplastic hepatocytes (DNs) and HCCs were generated from diethylnitrosamine (DEN)‐injected C57BL/6 male mice at 3–12 months.Results: Cyclin E/cdk2 was barely expressed in normal liver, but was readily detected in dysplastic hepatocytes, localizing to glutathione‐S transferase pi‐form positive cells dissected by laser‐dissection. Cyclin E kinase activity preceded cyclin D1, proliferating cell nuclear antigen expression in DNs and HCCs despite maximal p53 and p21 expression. We confirmed that cyclin E, rather than cyclin D1, is the proliferative driver in hepatocarcinogenesis by immunoprecipitation experiments demonstrating preferential binding of p21 to cyclin D1, allowing cyclin E‐mediated “escape” from G1/S checkpoint. We then showed cyclin E was responsible for regulating wild‐type p53 by knockdown experiments in primary HCC cells; cyclin E‐knockdown increased p53 and p21, diminished anti‐apoptotic Bcl‐XL and reduced cell viability. Conversely, blocking p53 augmented cyclin E, Bcl‐XL expression and increased proliferation. Physiological interactions between cyclin E/p53/p21 were confirmed in primary hepatocytes. miR‐34a,c were upregulated in dysplastic murine, human liver and HCCs compared with normal liver, and appeared to be linked to cyclin E/p53.Conclusion: Upregulation of functionally active cyclin E via miR34 with loss of p53 function is associated with cell‐cycle checkpoint failure increasing proliferative drive that favors hepatocarcinogenesis.
- 22 August 2013
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 28 (9) , 1545-1554
Cyclin E facilitates dysplastic hepatocytes to bypass G1/S checkpoint in hepatocarcinogenesis
Background and Aim: By array‐comparative genomic hybridization, we demonstrated cyclin E as one of seven genes associated with hepatocellular carcinoma (HCC) development in Ku70 DNA repair‐deficient mice. We therefore explored the hypothesis that during hepatocarcinogenesis, cyclin E kinase can overcome the inhibitory effects of p53 and establish whether abnormal miRNA(mi‐R)‐34, a co‐regulator of cyclin E and p53, can account for their interactions as “drivers” of HCC.Methods: Dysplastic hepatocytes (DNs) and HCCs were generated from diethylnitrosamine (DEN)‐injected C57BL/6 male mice at 3–12 months.Results: Cyclin E/cdk2 was barely expressed in normal liver, but was readily detected in dysplastic hepatocytes, localizing to glutathione‐S transferase pi‐form positive cells dissected by laser‐dissection. Cyclin E kinase activity preceded cyclin D1, proliferating cell nuclear antigen expression in DNs and HCCs despite maximal p53 and p21 expression. We confirmed that cyclin E, rather than cyclin D1, is the proliferative driver in hepatocarcinogenesis by immunoprecipitation experiments demonstrating preferential binding of p21 to cyclin D1, allowing cyclin E‐mediated “escape” from G1/S checkpoint. We then showed cyclin E was responsible for regulating wild‐type p53 by knockdown experiments in primary HCC cells; cyclin E‐knockdown increased p53 and p21, diminished anti‐apoptotic Bcl‐XL and reduced cell viability. Conversely, blocking p53 augmented cyclin E, Bcl‐XL expression and increased proliferation. Physiological interactions between cyclin E/p53/p21 were confirmed in primary hepatocytes. miR‐34a,c were upregulated in dysplastic murine, human liver and HCCs compared with normal liver, and appeared to be linked to cyclin E/p53.Conclusion: Upregulation of functionally active cyclin E via miR34 with loss of p53 function is associated with cell‐cycle checkpoint failure increasing proliferative drive that favors hepatocarcinogenesis.
- 1 December 2007
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (23) , 11368-11376
Genetic Alterations in the Tyrosine Kinase Transcriptome of Human Cancer Cell Lines
Protein tyrosine kinases (PTKs) play a critical role in the manifestation of cancer cell properties, and respective signaling mechanisms have been studied extensively on immortalized tumor cells. To characterize and analyze commonly used cancer cell lines with regard to variations in the primary structure of all expressed PTKs, we conducted a cDNA-based sequence analysis of the entire tyrosine kinase transcriptome of 254 established tumor cell lines. The profiles of cell line intrinsic PTK transcript alterations and the evaluation of 155 identified polymorphisms and 234 somatic mutations are made available in a database designated “Tykiva” (tyrosine kinome variant). Tissue distribution analysis and/or the localization within defined protein domains indicate functional relevance of several genetic alterations. The cysteine replacement of the highly conserved Y367 residue in fibroblast growth factor receptor 4 or the Q26X nonsense mutation in the tumor-suppressor kinase CSK are examples, and may contribute to cell line–specific signaling characteristics and tumor progression. Moreover, known variants, such as epidermal growth factor receptor G719S, that were shown to mediate anticancer drug sensitivity could be detected in other than the previously reported tumor types. Our data therefore provide extensive system information for the design and interpretation of cell line–based cancer research, and may stimulate further investigations into broader clinical applications of current cancer therapeutics. [Cancer Res 2007;67(23):11368–76]
- 1 December 2007
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (23) , 11368-11376
Genetic Alterations in the Tyrosine Kinase Transcriptome of Human Cancer Cell Lines
Protein tyrosine kinases (PTKs) play a critical role in the manifestation of cancer cell properties, and respective signaling mechanisms have been studied extensively on immortalized tumor cells. To characterize and analyze commonly used cancer cell lines with regard to variations in the primary structure of all expressed PTKs, we conducted a cDNA-based sequence analysis of the entire tyrosine kinase transcriptome of 254 established tumor cell lines. The profiles of cell line intrinsic PTK transcript alterations and the evaluation of 155 identified polymorphisms and 234 somatic mutations are made available in a database designated “Tykiva” (tyrosine kinome variant). Tissue distribution analysis and/or the localization within defined protein domains indicate functional relevance of several genetic alterations. The cysteine replacement of the highly conserved Y367 residue in fibroblast growth factor receptor 4 or the Q26X nonsense mutation in the tumor-suppressor kinase CSK are examples, and may contribute to cell line–specific signaling characteristics and tumor progression. Moreover, known variants, such as epidermal growth factor receptor G719S, that were shown to mediate anticancer drug sensitivity could be detected in other than the previously reported tumor types. Our data therefore provide extensive system information for the design and interpretation of cell line–based cancer research, and may stimulate further investigations into broader clinical applications of current cancer therapeutics. [Cancer Res 2007;67(23):11368–76]